Reuters: Global Markets: Amag names new CEO, allows shareholder to raise stake

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Amag names new CEO, allows shareholder to raise stake May 9th 2012, 22:00 Wed May 9, 2012 6:00pm EDT (Reuters) - Biopharmaceutical company Amag Pharmaceuticals Inc (AMAG.O) named William Heiden as its CEO, and allowed largest shareholder Adage Capital to raise its stake in the company up to 25 percent. Amag also said it was not actively looking for a sale anymore and would focus more on developing its anemia drug Feraheme, used to treat iron deficiency in adults with chronic kidney disease. Amag had hired Jefferies and Co as financial adviser to explore strategic alternatives, after its chief executive departed in November. Heiden, who replaces interim CEO Frank Thomas, joins AMAG from GTC Biotherapeutics Inc, where he was the chief executive officer. Investment management firm Adage Capital had reported a 19.5 percent passive stake in AMAG as of March 2, 2012. Amag shares were down 6 percent in extended trade. They had closed at $16.02 on Wednesday on the Nasdaq. (Reporting by Adithya Venkatesan in Bangalore; Editing by Saumyadeb Chakrabarty)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions